secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001140361-25-030822
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics Q2 net loss narrows to $7.4M; FDA grants RMAT for OPGx-LCA5
-------------------------------------------------------------------------

- Net loss $7.4M ($0.12/share) vs $7.8M ($0.30) in Q2 2024; revenue $2.9M from Viatris collaboration.
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 gene therapy.
- Positive 12-month adult and early pediatric data for OPGx-LCA5; 3-month pediatric data due Q3 2025.
- Phentolamine Phase 3 VEGA-3 (presbyopia) and LYNX-2 met primary endpoints; sNDA submission planned H2 2025.
- Cash $32.4M expected to fund operations into H2 2026; up to $3.6M non-dilutive funding secured for RDH12 and MERTK programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125030822/0001140361-25-030822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125030822/ef20053851_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-030822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer